ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
The Lancet
◽
10.1016/s0140-6736(11)61613-9
◽
2011
◽
Vol 378
(9807)
◽
pp. 1931-1939
◽
Cited By ~ 1195
Author(s):
Brian I Rini
◽
Bernard Escudier
◽
Piotr Tomczak
◽
Andrey Kaprin
◽
Cezary Szczylik
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Comparative Effectiveness
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13484037.14861147
◽
2012
◽
Author(s):
Thomas Powles
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Comparative Effectiveness
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
The Journal of Urology
◽
10.1016/j.juro.2012.04.069
◽
2012
◽
Vol 188
(2)
◽
pp. 412-413
Author(s):
Samir S. Taneja
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Comparative Effectiveness
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
Commentary on “Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase 3 trial.” B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D. Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim, R.J. Motzer
Urologic Oncology Seminars and Original Investigations
◽
10.1016/j.urolonc.2012.06.009
◽
2012
◽
Vol 30
(5)
◽
pp. 748
Author(s):
Donald L. Trump
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Comparative Effectiveness
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial
European Urology
◽
10.1016/j.eururo.2012.04.013
◽
2012
◽
Vol 62
(1)
◽
pp. 182-183
◽
Cited By ~ 1
Author(s):
Patrick A. Kenney
◽
Christopher G. Wood
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Comparative Effectiveness
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13484037.793515464
◽
2016
◽
Author(s):
David M Nanus
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Comparative Effectiveness
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma
SSRN Electronic Journal
◽
10.2139/ssrn.3427299
◽
2019
◽
Author(s):
Brian Rini
◽
Sumanta K. Pal
◽
Bernard J. Escudier
◽
Michael B. Atkins
◽
Thomas E. Hutson
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Study
◽
Label Study
Download Full-text
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(21)00693-8
◽
2022
◽
Author(s):
David Cella
◽
Robert J Motzer
◽
Cristina Suarez
◽
Steven I Blum
◽
Flavia Ejzykowicz
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Patient Reported Outcomes
◽
Advanced Renal Cell Carcinoma
◽
First Line
◽
Open Label
◽
Phase 3
◽
Patient Reported
Download Full-text
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)
Annals of Oncology
◽
10.1093/annonc/mdx371.026
◽
2017
◽
Vol 28
◽
pp. v307-v308
Author(s):
T. Powles
◽
R.J. Motzer
◽
D.J. George
◽
E. Jonasch
◽
S. Pal
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
◽
Plasma Biomarkers
Download Full-text
Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
Kidney Cancer
◽
10.3233/kca-190080
◽
2020
◽
Vol 4
(1)
◽
pp. 29-39
Author(s):
Nizar M. Tannir
◽
Thomas Powles
◽
Bernard Escudier
◽
Frede Donskov
◽
Viktor Grünwald
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Clinical Outcomes
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
Download Full-text
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Nature Medicine
◽
10.1038/s41591-020-1044-8
◽
2020
◽
Vol 26
(11)
◽
pp. 1733-1741
◽
Cited By ~ 8
Author(s):
Robert J. Motzer
◽
Paul B. Robbins
◽
Thomas Powles
◽
Laurence Albiges
◽
John B. Haanen
◽
...
Keyword(s):
Renal Cell Carcinoma
◽
Cell Carcinoma
◽
Renal Cell
◽
Advanced Renal Cell Carcinoma
◽
Phase 3
◽
Biomarker Analysis
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close